Primary human hepatocytes (PHHs) and other hepatic cell models possess several limitations. For instance, PHH’s large lot-to-lot variation requires qualification tests with each lot, resulting in high costs and increased lead time. Furthermore, other non-primary hepatic cells can have insufficient fold induction in some lots and conditions.
This presentation will introduce Corning® HepatoCells for ADME/Tox studies. Derived from primary human hepatocytes, Corning HepatoCells are a renewable, hepatocyte-like cell line that retains most of the physiological properties of their parental hepatocytes such as mature hepatocyte-like morphology and induction response to prototypical inducers of CYP3A4, 1A2, and 2B6. Characterization of Corning HepatoCells for ADME/Tox studies will be presented, along with data demonstrating how the model system can be used for prediction of clinical CYP induction.
Dr. Rongjun Zuo is currently a Senior Development Scientist in the Corning Life Sciences ADME group. She has more than 7 years experience developing cell-based assays for in vitro ADME study including metabolic stability, drug-drug interactions, and transporter assays, with a focus on hepatocyte product applications. Dr. Zuo obtained her Ph.D. degree from University of Connecticut working on the molecular biology of bacteria biofilm. She obtained her post-doc training at the Center for Engineering in Medicine affiliated with Massachusetts General Hospital, the Harvard Medical School, working on liver tissue engineering.